When Should Patients with NETs Be Advised Not To Take GLP-1 Agents? | CancerNetwork

News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Trending on CancerNetwork

Precision Medicine With Duvelisib and the Evolving Landscape of Lymphoma

Novel HP1K Inhibitor Shows Favorable Responses in ccRCC, Solid Tumors

117 Risk of Recurrence (ROR) Among Patients With HR+/HER2− Early Breast Cancer (EBC) Involving 1-3 Axillary Lymph Nodes (N1): A Real-World Evaluation

How Is Zoldonrasib Different From Other Therapies in KRAS G12D+ NSCLC?

119 Progression-Free Survival (PFS) and Overall Survival (OS) Results From the Phase 3 MONALEESA-3 Trial of Postmenopausal Patients With Hormone Receptor–Positive (HR+)/Human Epidermal Growth Factor Receptor 2–Negative (HER2−) Advanced Breast Cancer (ABC) Treated With Ribociclib (RIB) + Fulvestrant (FUL): A Subgroup Analysis of Patients With Invasive Lobular Carcinoma (ILC)